Skip to main content
. 2012 Dec 13;16(12):3062–3073. doi: 10.1111/j.1582-4934.2012.01648.x

Fig 5.

Fig 5

Lamstatin and CP17 inhibit lymphangiogenesis in a murine model of tumour-induced lymphangiogenesis. LNM35 tumour cells, expressing EGFP, were injected intradermally into ears of NOD/SCID/gamma mice with or without lamstatin or CP17 and Matrigel. No tumour = 200 μl Matrigel bolus only. Vehicle = tumour cells, Matrigel and vehicle (292.2 ng/l EDTA, pH 3.5). Lamst = Lamstatin either 10 or 100 μg/ml in a 200 μl bolus of LNM35 and Matrigel. CP17 = CP17 10 or 100 μg/ml in a 200 μl bolus of LNM35 and Matrigel. Images of representative staining for treatment of tumour-induced lymphangiogenesis with lamstatin and CP17 (lamstatin: no tumour n = 3, vehicle n = 11, 10 and 100 μg/ml lamstatin, n = 8 and n = 9 mice; CP17: no tumour n = 3, vehicle n = 11, 10 and 100 μg/ml CP17, n = 8 and n = 6 mice respectively). White layer = LYVE-1, lymphatics; Green layer = LNM35 tumour; Red layer = PECAM-1 (CD31), blood vasculature. Scale bar represents 200 μm.